Reding Pharmaceutical CD3/CD20 dual resistance was approved to conduct clinical trials in China.

REGN 1979 was developed by Regeneration, and On April 8, Reding Pharmaceuticals spent US$190 million to introduce its development interests in Greater China.
the drug's use in the treatment of diffuse large B-cell lymphoma (DLBCL) and fable lymphoma (FL) has been approved by the FDA as an orphan drug, which is the two most common subtypes of B-NHL.
REN1979 DLBCL is a highly invasive type of B-NHL in which nearly 50 percent of patients with advanced patients develop the disease after first-line treatment (i.e., recurrence or recurring).
patients with relapsed or difficult-to-treat (R/R) DLBCL, current treatment options are limited and the prognosis is poor.
FL is a slow-growing (inert) B-NHL, and most cases are diagnosed at a late stage.
although the mid-life of patients with advanced FL is 8 to 15 years, current treatments are incurable and most patients will relapse within five years, regardless of the treatment.
in some cases, the FL changes to DLBCL, where treatment is usually performed in the same way as DLBCL is treated.
.